三阴性乳腺癌基因学分子分型和个体化治疗新进展

发布时间：2018-05-12 22:51

本文选题：三阴性乳腺癌 + 分子分型　；参考：《中华肿瘤防治杂志》2016年17期

【摘要】：目的三阴性乳腺癌(triple negative breast cancer,TNBC)作为乳腺癌的一种特殊类型,具有高侵袭性,极易出现局部复发和远处转移。近年来关于TNBC进一步亚分类,并且针对各亚型进行相应靶向治疗的基础研究和临床研究均较多。本研究对国内外TNBC的分子分型和个体化治疗新进展进行综述分析。对国内外三阴性乳腺癌(triple negative breast cancer,TNBC)的分子分型以及个体化治疗新进展进行综述分析。方法应用PubMed及CNKI期刊全文数据库检索系统,以"三阴性乳腺癌、TNBC、分子分型、治疗"等为关键词,检索2011-01-2016-05相关文献,共检索到英文文献240条,中文文献449条。纳入标准:(1)TNBC的生物学功能;(2)TNBC的分子分型;(3)TNBC的个体化治疗。剔除标准:(1)乳腺癌的分子分型;(2)乳腺癌的个体化治疗。根据剔除标准剔除中文文献130条,英文文献141条,最后纳入分析63篇文献。结果 TNBC从基因学角度分为6个亚型,针对每个亚型均有不同的个体化治疗靶向药物,包括表皮生长因子受体(epidermal growth factor receptor,EGFR)抑制剂、铂类、聚腺苷酸二磷酸核糖转移酶(poly-AD-ribose polymerase,PARP)抑制剂、蒽环/紫衫、免疫治疗、血管内皮生长因子受体(vascular endothelial growth factor receptor,VEGFR)抑制剂、雄激素受体(androgen receptor,AR)拮抗剂以及各靶向治疗手段的联合使用。结论 TNBC是异质性疾病,其分子分型的确定对于理解肿瘤的生物学特征和临床行为,以及发展TNBC个体化治疗都是必需的。由于TNBC肿瘤信号通路之间的交联,发展不同靶向药物的联合应用才有望真正的提高该疾病的总生存。
[Abstract]:Objective as a special type of breast cancer, triple negative breast cancer is highly invasive and prone to local recurrence and distant metastasis. In recent years, there are many basic and clinical studies on the subclassification of TNBC and the corresponding targeted therapy for each subtype. In this study, the molecular typing and individualized therapy of TNBC were reviewed and analyzed. The molecular typing and new progress of individualized treatment of triple negative breast cancer in China and abroad were reviewed and analyzed. Methods using PubMed and CNKI periodical full-text database retrieval system, using the key words of "tri-negative breast cancer, molecular typing, treatment" as the key words, to search for 2011-01-2016-05 related literature, a total of 240 articles in English and 449 articles in Chinese were retrieved. The biological function of TNBC and the molecular typing of TNBC were classified into standard 1: 1, and the individualized treatment of TNBC was carried out. Exclude Standard 1) Molecular typing of Breast Cancer / 2) individualized treatment of Breast Cancer. 130 articles of Chinese literature and 141 articles of English literature were excluded according to the exclusion criteria, and 63 articles were included in the analysis. Results TNBC was divided into 6 subtypes from a genetic point of view. There were different individualized targeted drugs for each subtype, including epidermal growth factor receptor inhibitor, platinum, polyadenylate ribonucleosyltransferase poly-AD-ribose polymerase inhibitor. Anthracycline / Violet, immunotherapy, vascular endothelial growth factor receptor (VEGF) inhibitor, androgen receptor antagonist, androgen receptor antagonist and the combination of various targeted therapeutic methods. Conclusion TNBC is a heterogeneous disease, and the determination of its molecular typing is necessary to understand the biological characteristics and clinical behavior of tumor and to develop individual treatment of TNBC. Because of the cross-linking between TNBC tumor signaling pathways, the development of the combination of different targeted drugs is expected to improve the overall survival of the disease.
【作者单位】：湖北省肿瘤医院乳腺外科·湖北省乳腺病防治研究中心;
【基金】：湖北省卫生计生委重点科研项目(WJ2015MA016)
【分类号】：R737.9

【相似文献】